-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

Benzinga·06/01/2026 16:36:15
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.